drugset / Trial / NCT00792246
Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease
Phase 1
Completed
5 enrolled
Phillip Brian Smith
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
Determine how much voriconazole is absorbed when the product is given by mouth to children with extensive graft versus host disease after a stem cell transplantation and determine the correct dosing of voriconazole in this population. Hypothesis: Children with gastrointestinal graft versus host disease will have decreased absorption of oral voriconazole and require higher doses of voriconazole in order to prevent or treat fungal infections.
Timeline
- Start
- 2008-12
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voriconazole | Small molecule | — | Oral |